In support of these observations, the literature data shows that HER2-amplified cell lines and tumor samples both have elevated FASN and ACAT1 function (fatty acid synthesis), leading to poor prognosis131–134 and inhibitors to such targets enhance the efficacy of anti-HER2 therapies135. The gene discussed is ERBB2; the disease is neoplasm.